ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

ArriVent’s ARR-217 shows strong Phase 1 efficacy but remains years from commercial impact.

What the company is saying

ArriVent BioPharma is highlighting initial Phase 1 results for ARR-217 (MRG007), its cadherin-17-targeting antibody-drug conjugate for gastrointestinal cancers, developed with Lepu Biopharma. The company emphasizes a 44.8% objective response rate and 93.1% disease control rate at the 6 mg/kg Q3W dose in heavily pretreated colorectal cancer patients, positioning these as evidence of strong anti-tumor activity. CEO Bing Yao frames the results as a foundation for advancing to Phase 1b dose optimization, stressing both efficacy and a manageable safety profile. The announcement details the multicenter, open-label trial (NCT07066657) in the US and China, with 123 patients treated across six dose levels, and notes that most responders remained on treatment at the August 5, 2026 cutoff. The company claims ARR-217 is the first ADC from its pipeline to enter clinical development and sets expectations for dose optimization data in 2027. The tone is confident, focusing on clinical milestones and omitting any financial or commercial projections.

What the data suggests

The disclosed data show that at the 6 mg/kg Q3W dose, 44.8% (13/29) of pretreated colorectal cancer patients achieved an objective response, with a 93.1% (27/29) disease control rate. Across doses of 4 mg/kg Q3W and higher, the objective response rate was 34.2% (25/73) and disease control rate was 91.8%. Most treatment-related adverse events were Grade 1/2, but 30.1% (37/123) of all patients experienced Grade 3 or higher adverse events, including 12.2% neutropenia and 8.9% diarrhea. At the 6 mg/kg Q3W dose, Grade 3 or higher adverse events occurred in 20.4% (10/49) of patients, with 2.0% (1/49) experiencing Grade 3 or higher diarrhea. No Grade 5 treatment-related adverse events or interstitial lung disease were observed. The trial has moved into Phase 1b dose optimization at 5 and 6 mg/kg Q3W, with further data expected in 2027. The evidence supports meaningful anti-tumor activity in a heavily pretreated population, but the safety profile includes a notable rate of severe adverse events. No financial, commercial, or long-term survival data are provided.

Analysis

The announcement provides detailed, specific Phase 1 clinical trial results for ARR-217, including patient numbers, dose levels, response rates, and adverse event frequencies. The majority of claims are realised and supported by numerical data, with only a small portion of the language being forward-looking (e.g., anticipation of Phase 1b dose optimization data in 2027). There is no evidence of exaggerated or promotional language; the tone is positive but proportionate to the disclosed results. No large capital outlay or immediate commercial impact is discussed, and the next milestone (dose optimization data) is not expected until 2027, placing benefit realisation in the long-term category. The absence of financial or profitability data is not a deficiency for an early-stage biotech clinical update. Overall, the narrative closely matches the evidence, with minimal hype.

Risk flags

• ●Clinical risk is high, as the data are from an early Phase 1 trial with a small subset of patients at the most active dose. Efficacy and safety in later-phase, larger, and more diverse populations may differ significantly.
• ●The safety profile, while described as manageable, includes 30.1% Grade 3 or higher treatment-related adverse events, with notable rates of neutropenia (12.2%) and diarrhea (8.9%). These rates could limit dosing or broader applicability.
• ●Timeline risk is substantial, as the next data readout is not expected until 2027, and any commercial or regulatory milestones are likely several years away. Investors face a long wait with no interim financial or commercial catalysts disclosed.
• ●No financial data, cash runway, or partnership economics are disclosed, leaving investors unable to assess funding sufficiency or the commercial terms with Lepu Biopharma outside Greater China.
• ●The company’s claims about the majority of responders remaining on treatment lack precise numerical backing, introducing some uncertainty about durability of response.

Bottom line

ArriVent’s Phase 1 data for ARR-217 in heavily pretreated colorectal cancer patients show promising response and disease control rates, especially at the 6 mg/kg Q3W dose, but are offset by a significant rate of severe adverse events. The company is advancing to Phase 1b dose optimization, with further data not expected until 2027, meaning any commercial or regulatory impact is distant. No financial metrics, cash position, or partnership economics are disclosed, leaving a gap in assessing the company’s operational runway or potential upside from the Lepu Biopharma collaboration. The announcement is credible and data-rich for an early-stage biotech, but investors should recognize the long timeline, high clinical risk, and absence of near-term catalysts. The most important takeaway is that while ARR-217’s early efficacy signal is encouraging, the path to value realization remains long and uncertain.

Announcement summary

(NASDAQ:AVBP) ArriVent BioPharma, Inc. announced initial Phase 1 results for ARR-217 (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The results were presented at the 2026 European Society for Medical Oncology (ESMO) Congress. Bing Yao, Ph.D., Chief Executive Officer of ArriVent, stated that the responses observed in heavily pretreated patients and the manageable safety profile support advancing ARR-217 into a Phase 1b dose optimization study. The ongoing multicenter, open-label Phase 1 study (NCT07066657) is being conducted in the US and China, focusing on patients with unresectable, locally advanced, or metastatic solid tumors, particularly colorectal, pancreatic, and other GI cancers. As of the August 5, 2026 data cutoff, 123 patients with heavily pretreated GI malignancies were treated across 6 dose levels (2 mg/kg to 8 mg/kg), including 113 patients with colorectal cancer (CRC). At the 6 mg/kg Q3W dose, a 44.8% (13/29) objective response rate (ORR) was observed in pre-treated CRC patients, including 7 confirmed partial responses, 4 partial responses pending confirmation, and 2 unconfirmed partial responses. At the same dose, the disease control rate (DCR) was 93.1% (27/29). At doses 4 mg/kg Q3W and higher, a 34.2% (25/73) ORR and a 91.8% DCR were observed in CRC patients. The majority of responding patients remained on study treatment as of the data cutoff. The safety profile was generally well tolerated, with the most common treatment-related adverse events being Grade 1/2. Across all doses, 30.1% (37/123) of patients experienced Grade 3 or higher treatment-related adverse events, including neutropenia (12.2%) and diarrhea (8.9%). At the 6.0 mg/kg Q3W dose, Grade 3 or higher TRAE was 20.4% (10/49), including 2.0% diarrhea (1/49). No grade 5 TRAE or interstitial lung disease (ILD) was observed. ARR-217 has advanced into Phase 1b dose optimization at doses of 5 and 6 mg/kg Q3W, with further dose optimization data expected in 2027. ARR-217 (MRG007) is a cadherin-17 (CDH17)-targeted ADC utilizing a glycan-linked, exatecan-based payload. ArriVent obtained exclusive rights to develop and commercialize ARR-217 worldwide outside of Greater China under a collaboration agreement with Lepu Biopharma Co., Ltd. ARR-217 is the lead clinical candidate from ArriVent's ADC portfolio.

Disagree with this article?